HTRS2025.P1.2 Effect of Baseline Target Joints on Annualized Bleeding Rate and Management of Breakthrough Bleeding in Patients With Hemophilia A or B and Inhibitors: Results From Concizumab Phase 3 Explorer7

Slični predmeti

• Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study
  od: Huyen Tran, i dr.
  Izdano: (2024-05-01)
• Concizumab prophylaxis in a 2-year-old patient with severe hemophilia B and inhibitor: a case report
  od: Mandy Yuan, i dr.
  Izdano: (2026-07-01)
• Case Report: Severe hemophilia B patient with inhibitor and anaphylaxis reaction to FIX, successfully managed with concizumab prophylaxis therapy
  od: Elisa Bonetti, i dr.
  Izdano: (2025-04-01)
• Prophylaxis in Hemophilia
  od: Júlia Plentz Portich, i dr.
  Izdano: (2023-05-01)
• Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors
  od: Silvia Linari, i dr.
  Izdano: (2026-05-01)